神経内分泌系癌：世界の臨床試験レビュー（2014年上半期）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Neuroendocrine Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Neuroendocrine Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Neuroendocrine Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Neuroendocrine Cancer 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Neuroendocrine Cancer Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Neuroendocrine Cancer 33
Apr 09, 2013: ArQule’s New AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase I Trial 33
Oct 25, 2008: Callisto Pharmaceuticals To Open Atiprimod Phase II Extension Trial In Neuroendocrine Cancer 33
Oct 07, 2008: Neotropix Announces The Expansion Of On-going Clinical Trial For Adult Neuroendocrine Cancers 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Novartis AG 35
Clinical Trial Overview of Novartis AG 35
Pfizer Inc. 38
Clinical Trial Overview of Pfizer Inc. 38
Ipsen S.A. 39
Clinical Trial Overview of Ipsen S.A. 39
F. Hoffmann-La Roche Ltd. 40
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 40
Progenics Pharmaceuticals, Inc. 41
Clinical Trial Overview of Progenics Pharmaceuticals, Inc. 41
Tekmira Pharmaceuticals Corp. 42
Clinical Trial Overview of Tekmira Pharmaceuticals Corp. 42
Threshold Pharmaceuticals, Inc. 43
Clinical Trial Overview of Threshold Pharmaceuticals, Inc. 43
Merck & Co., Inc. 44
Clinical Trial Overview of Merck & Co., Inc. 44
Eli Lilly and Company 45
Clinical Trial Overview of Eli Lilly and Company 45
Daiichi Sankyo Company, Limited 46
Clinical Trial Overview of Daiichi Sankyo Company, Limited 46
Clinical Trial Overview of Top Institutes / Government 47
National Cancer Institute 47
Clinical Trial Overview of National Cancer Institute 47
The University of Texas M. D. Anderson Cancer Center 49
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 49
Memorial Sloan Kettering Cancer Center 50
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 50
Stanford University 51
Clinical Trial Overview of Stanford University 51
Grupo Espanol de Tumores Neuroendocrinos 52
Clinical Trial Overview of Grupo Espanol de Tumores Neuroendocrinos 52
University of Wisconsin Madison 53
Clinical Trial Overview of University of Wisconsin Madison 53
The University of Iowa 54
Clinical Trial Overview of The University of Iowa 54
University of California, San Francisco 55
Clinical Trial Overview of University of California, San Francisco 55
Alberta Health Services 56
Clinical Trial Overview of Alberta Health Services 56
Five Key Clinical Profiles 57
Appendix 121
Abbreviations 121
Definitions 121
Research Methodology 122
Secondary Research 122
About GlobalData 123
Contact Us 123
Disclaimer 123
Source 124